← Back to Search

Calibration of MR and PET-MR Imaging Protocols for Imaging

N/A
Recruiting
Led By Daniel S. Berman, M.D.
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one day
Awards & highlights

Study Summary

This trial is to help with the technical aspects of the Siemens Biograph mMR and 3T Siemens Vida MR scanner.

Who is the study for?
This trial is for adults over 18 years old. For PET-MR imaging, it's for outpatients already getting a standard 18FDG-PET scan at CSMC. For MR-only imaging, it's open to volunteers responding to ads from the BIRI Research Imaging Core. Pregnant individuals or those with contraindications to MRI (like metallic implants or severe claustrophobia) cannot participate.Check my eligibility
What is being tested?
The study is calibrating two types of scanners: the Siemens Biograph mMR scanner for combined PET-MR images and the Siemens Vida 3T MR scanner for MR images only. These are non-experimental FDA-approved devices used according to federal guidelines.See study design
What are the potential side effects?
Since this trial involves standard imaging procedures that are non-invasive and use approved equipment, significant side effects are not expected. However, typical MRI-related discomforts like loud noises during scanning or issues related to lying still may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one day
This trial's timeline: 3 weeks for screening, Varies for treatment, and one day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Positron-Emission Tomography

Trial Design

3Treatment groups
Experimental Treatment
Group I: PET-MR imaging on Biograph mMR scannerExperimental Treatment1 Intervention
Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
Group II: MR-only imaging on Biograph mMR scannerExperimental Treatment1 Intervention
Participants will undergo research MR-only imaging on Biograph mMR scanner.
Group III: MR imaging on the Siemens Vida 3T MR scannerExperimental Treatment1 Intervention
Participants will undergo research MR imaging on the Siemens MR scanner

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
500 Previous Clinical Trials
164,823 Total Patients Enrolled
22 Trials studying Coronary Artery Disease
17,387 Patients Enrolled for Coronary Artery Disease
Daniel S. Berman, M.D.5.02 ReviewsPrincipal Investigator - Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
1 Previous Clinical Trials
2,137 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
2,137 Patients Enrolled for Coronary Artery Disease

Media Library

PET-MR imaging on Biograph mMR scanner Clinical Trial Eligibility Overview. Trial Name: NCT02249520 — N/A
Coronary Artery Disease Research Study Groups: PET-MR imaging on Biograph mMR scanner, MR-only imaging on Biograph mMR scanner, MR imaging on the Siemens Vida 3T MR scanner
Coronary Artery Disease Clinical Trial 2023: PET-MR imaging on Biograph mMR scanner Highlights & Side Effects. Trial Name: NCT02249520 — N/A
PET-MR imaging on Biograph mMR scanner 2023 Treatment Timeline for Medical Study. Trial Name: NCT02249520 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people presently signing up to participate in this trial?

"That is correct, the clinical trial is listed as currently recruiting patients on clinicaltrials.gov. The trial was originally posted on September 1st, 2014 and was last updated on March 7th, 2022. The study is looking for 40 patients at 1 site."

Answered by AI
~25 spots leftby Dec 2040